argenx SE (ARGX.BR)
EUR 610.0
(1.77%)
EUR 610.0
(1.77%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -272.91 Million EUR | 61.54% |
| 2022 | -709.59 Million USD | -73.81% |
| 2021 | -408.26 Million USD | 37.24% |
| 2020 | -650.54 Million EUR | -256.37% |
| 2019 | -182.54 Million EUR | -139.47% |
| 2018 | -76.23 Million EUR | -126.32% |
| 2017 | -33.68 Million EUR | -49.84% |
| 2016 | -22.47 Million EUR | -34.28% |
| 2015 | -16.74 Million EUR | -33.48% |
| 2014 | -12.54 Million EUR | -48.14% |
| 2013 | -8.46 Million EUR | 33.99% |
| 2012 | -12.82 Million EUR | -185.59% |
| 2011 | -4.49 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 29.06 Million EUR | 47.27% |
| 2024 Q1 | -61.59 Million USD | 37.98% |
| 2023 Q3 | -72.64 Million USD | 23.02% |
| 2023 Q1 | -28.87 Million USD | 25.23% |
| 2023 Q2 | -94.36 Million USD | -226.86% |
| 2023 FY | -272.91 Million EUR | 61.54% |
| 2023 Q4 | -99.17 Million USD | -36.52% |
| 2022 FY | -709.59 Million USD | -73.81% |
| 2022 Q3 | -235.04 Million USD | -12.6% |
| 2022 Q4 | -38.61 Million USD | 83.57% |
| 2022 Q1 | -227.18 Million USD | 4.47% |
| 2022 Q2 | -208.74 Million USD | 8.12% |
| 2021 Q1 | -40.43 Million EUR | 87.49% |
| 2021 FY | -408.26 Million USD | 37.24% |
| 2021 Q2 | 103.6 Million USD | 356.23% |
| 2021 Q3 | -233.61 Million USD | -325.5% |
| 2021 Q4 | -237.81 Million USD | -1.8% |
| 2020 Q4 | -323.28 Million EUR | 0.0% |
| 2020 FY | -650.54 Million EUR | -256.37% |
| 2020 Q2 | -205.63 Million EUR | 0.0% |
| 2019 Q1 | 7.57 Million EUR | 122.36% |
| 2019 FY | -182.54 Million EUR | -139.47% |
| 2019 Q4 | -92.9 Million EUR | -272.59% |
| 2019 Q3 | -24.93 Million EUR | 57.65% |
| 2019 Q2 | -58.88 Million EUR | -876.89% |
| 2018 Q2 | -1.44 Million EUR | 93.37% |
| 2018 Q3 | -19.12 Million EUR | -1224.58% |
| 2018 FY | -76.23 Million EUR | -126.32% |
| 2018 Q1 | -21.76 Million EUR | -51.72% |
| 2018 Q4 | -33.89 Million EUR | -77.2% |
| 2017 Q1 | -8.98 Million EUR | -7.25% |
| 2017 Q2 | -387.54 Thousand EUR | 95.69% |
| 2017 Q4 | -14.34 Million EUR | -44.05% |
| 2017 Q3 | -9.96 Million EUR | -2470.1% |
| 2017 FY | -33.68 Million EUR | -49.84% |
| 2016 Q3 | -5.91 Million EUR | -22.86% |
| 2016 Q1 | -3.36 Million EUR | 37.72% |
| 2016 FY | -22.47 Million EUR | -34.28% |
| 2016 Q2 | -4.81 Million EUR | -43.09% |
| 2016 Q4 | -8.37 Million EUR | -41.6% |
| 2015 Q2 | -4.64 Million EUR | -44.03% |
| 2015 FY | -16.74 Million EUR | -33.48% |
| 2015 Q4 | -5.4 Million EUR | -56.02% |
| 2015 Q3 | -3.46 Million EUR | 25.45% |
| 2015 Q1 | -3.22 Million EUR | 29.28% |
| 2014 Q2 | -3.67 Million EUR | -43.47% |
| 2014 Q3 | -1.74 Million EUR | 52.49% |
| 2014 Q4 | -4.56 Million EUR | -161.37% |
| 2014 FY | -12.54 Million EUR | -48.14% |
| 2014 Q1 | -2.56 Million EUR | -22.83% |
| 2013 Q2 | -3.95 Million EUR | -70.73% |
| 2013 Q3 | -102.69 Thousand EUR | 97.41% |
| 2013 Q4 | -2.08 Million EUR | -1930.17% |
| 2013 Q1 | -2.31 Million EUR | 0.0% |
| 2013 FY | -8.46 Million EUR | 33.99% |
| 2012 FY | -12.82 Million EUR | -185.59% |
| 2011 FY | -4.49 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -7657.684% |
| ABIVAX Société Anonyme | -147.74 Million EUR | -84.727% |
| Adocia SA | -21.16 Million EUR | -1189.648% |
| Aelis Farma SA | -5.07 Million EUR | -5274.465% |
| Biophytis S.A. | -17.02 Million EUR | -1502.933% |
| Advicenne S.A. | -7.03 Million EUR | -3781.6% |
| genOway Société anonyme | 1.56 Million EUR | 17510.032% |
| IntegraGen SA | -171.39 Thousand EUR | -159128.064% |
| Medesis Pharma S.A. | -3.95 Million EUR | -6792.687% |
| Neovacs S.A. | -8.74 Million EUR | -3021.369% |
| NFL Biosciences SA | -3.74 Million EUR | -7186.532% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 344824.968% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -8506.745% |
| Sensorion SA | -22.06 Million EUR | -1136.959% |
| Theranexus Société Anonyme | -6.82 Million EUR | -3897.03% |
| TME Pharma N.V. | -6.73 Million EUR | -3951.593% |
| Valbiotis SA | -7.36 Million EUR | -3604.062% |
| TheraVet SA | -1.57 Million EUR | -17275.316% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -1241.503% |
| BioSenic S.A. | -28.77 Million EUR | -848.347% |
| Celyad Oncology SA | -8.44 Million EUR | -3130.532% |
| DBV Technologies S.A. | -67.26 Million EUR | -305.705% |
| Galapagos NV | 211.69 Million EUR | 228.918% |
| Genfit S.A. | -28.89 Million EUR | -844.54% |
| GeNeuro SA | -14.75 Million EUR | -1749.396% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -1674.482% |
| Innate Pharma S.A. | -7.57 Million EUR | -3505.222% |
| Inventiva S.A. | -110.42 Million EUR | -147.148% |
| MaaT Pharma SA | -19.71 Million EUR | -1284.162% |
| MedinCell S.A. | -25.03 Million EUR | -990.004% |
| Nanobiotix S.A. | -39.7 Million EUR | -587.444% |
| Onward Medical N.V. | -36.18 Million EUR | -654.306% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -8039.575% |
| OSE Immunotherapeutics SA | -23 Million EUR | -1086.434% |
| Oxurion NV | -18.96 Million EUR | -1338.744% |
| Pharming Group N.V. | -9.75 Million EUR | -2697.241% |
| Poxel S.A. | -35.09 Million EUR | -677.758% |
| GenSight Biologics S.A. | -26.22 Million EUR | -940.867% |
| Transgene SA | -22.32 Million EUR | -1122.301% |
| Financière de Tubize SA | 88.15 Million EUR | 409.599% |
| UCB SA | 343 Million EUR | 179.567% |
| Valneva SE | -101.42 Million EUR | -169.07% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -862.936% |